Patent ID: 9410962
Filing Date: 2016-08-09
CPC Classification: G01N

Claim Text:
1. A process for monitoring compliance of gluten concentration in a gluten free diet comprising: (a) isolating a fecal sample from a human ingesting a gluten free diet; (b) treating the fecal sample of step (a) with a hydroalcoholic solution, the treating of the fecal sample providing extracted immunotoxic gluten peptides; (c) contacting the extracted peptides of step b) with at least one monoclonal antibody which specifically binds the gluten immunotoxic peptides having epitopes of including any sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 6, the contacting of the extracted peptides with the at least one monoclonal antibody forming monoclonal antibody-gluten peptide complexes; (d) detecting the monoclonal antibody-gluten peptide complexes formed in step (c); (e) quantitating the extracted immunotoxic peptides based on the detection of at least one of the monoclonal antibody-gluten peptide complexes; and (f) monitoring the quantitated immunotoxic peptides of step (e), wherein an increase of the quantity of the extracted peptides above 160 ng/g of feces is indicative of non-compliance of the gluten concentration in the gluten free diet.